中晚期肝癌免疫治疗现状与前景

近年来，随着肿瘤免疫治疗的飞速发展及对肝癌免疫微环境认识的不断深入，以免疫检查点抑制剂为导向的新型系统治疗越来越受到关注。除此之外还有免疫治疗方法如肿瘤疫苗、溶瘤病毒、细胞因子等传统免疫方法也在肿瘤治疗中发挥着一定作用。而基于当前的多学科协作诊疗模式，肝癌的免疫治疗更多强调联合治疗，目前免疫联合治疗的方向主要有:双免疫检查点抑制剂联合、免疫检查点联合放化疗、免疫检查点联合抗血管生成药物等。对于肝癌的免疫治疗呈现了多方案的局面。因此，本文就肝癌免疫治疗的现状与前景进行综述，以期助于临床更好的应用。

The present situation and prospect of immunotherapy for advanced hepatocellular carcinoma

In recent years,with the rapid development of tumor immunotherapy and the deepening understanding of the immune microenvironment of hepatocellular carcinoma,more and more attention has been paid to the novel systemic therapy based on immune checkpoint inhibitors.In addition,there are also immunotherapy methods,such as tumor vaccines,oncolytic viruses,cytokines and other traditional immune methods,which also play a certain role in tumor therapy.Based on the current multidisciplinary collaborative diagnosis and treatment model,the immunotherapy for liver cancer emphasizes more on combination therapy.At present,the direction of immunotherapy combination mainly includes:double immunocheckpoint inhibitor combination,immunocheckpoint combination with chemoradiotherapy,immunocheckpoint combination with anti-angiogenic drugs.In the treatment of liver tumors,immunotherapy has achieved results.Immunotherapy for hepatocellular carcinoma,presents a situation of multiple programs.Therefore,the present situation and prospect of immunotherapy for hepatocellular carcinoma are reviewed in this paper in order to help better clinical application.